LEADER 03867nam 22006615 450 001 9910300341003321 005 20200706043728.0 010 $a3-319-08350-3 024 7 $a10.1007/978-3-319-08350-6 035 $a(CKB)3710000000277579 035 $a(EBL)1965187 035 $a(SSID)ssj0001386519 035 $a(PQKBManifestationID)11759736 035 $a(PQKBTitleCode)TC0001386519 035 $a(PQKBWorkID)11351612 035 $a(PQKB)11014150 035 $a(MiAaPQ)EBC1965187 035 $a(DE-He213)978-3-319-08350-6 035 $a(PPN)183087216 035 $a(EXLCZ)993710000000277579 100 $a20141106d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aHandbook of Chronic Myeloid Leukemia$b[electronic resource] /$fby Timothy P Hughes, David M Ross, Junia V Melo 205 $a1st ed. 2014. 210 1$aCham :$cSpringer International Publishing :$cImprint: Adis,$d2014. 215 $a1 online resource (74 p.) 300 $aDescription based upon print version of record. 311 $a3-319-08349-X 320 $aIncludes bibliographical references. 327 $aEpidemiology and risk factors.- Pathophysiology.-Diagnosis -- Management of patients with CML -- Challenges of treatment: treatment-resistant CML -- Useful resources for your patients and caregivers. 330 $aThis concise, clinically focused pocket handbook assembles and synthesizes the latest developments and trends in the diagnosis and treatment of CML and provides an authoritative and convenient summary of the latest progress in TKI trials, the molecular monitoring of CML responses, and the development of new therapies to overcome resistance and improve patient care. Chronic myeloid leukemia (CML) is a rare type of leukemia (1?2 per 100,000 people) but is the most common chronic myeloproliferative neoplasm. CML remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level; CML was the first cancer to be associated with a recurring chromosome abnormality, which generates the Philadelphia (Ph) chromosome and its associated fusion gene BCR-ABL1. The clinical outcome for patients with CML has changed dramatically in the past 15 years and this has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein. A number of first-, second- and third-generation TKIs are now available for the treatment of CML, although a number of treatment challenges remain, not least the development of treatment-resistant CML. Parallel to the development of specific drugs for treating CML, major advances have been made in the field of disease monitoring and standardization of response criteria. . 606 $aHematology 606 $aOncology   606 $aPharmacotherapy 606 $aHematology$3https://scigraph.springernature.com/ontologies/product-market-codes/H3307X 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000 615 0$aHematology. 615 0$aOncology  . 615 0$aPharmacotherapy. 615 14$aHematology. 615 24$aOncology. 615 24$aPharmacotherapy. 676 $a610 676 $a615.1 676 $a616.15 676 $a616994 700 $aHughes$b Timothy P$4aut$4http://id.loc.gov/vocabulary/relators/aut$0755260 702 $aRoss$b David M$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aMelo$b Junia V$4aut$4http://id.loc.gov/vocabulary/relators/aut 906 $aBOOK 912 $a9910300341003321 996 $aHandbook of Chronic Myeloid Leukemia$92494444 997 $aUNINA